Together with the epigenetic and transcriptional silencing of MAB21L2/LRBA in SVZM+ tumors found in our study, these data provide a plausible explanation for a prognostic and potentially functional relevance of these genes at the tumor immune microenvironment interface contributing to the observed inferior clinical outcome in SVZM+ GBM. Here, MAB21L2 is linked to glioblastoma.